AXSM in the 13F filings
Axsome Therapeutics Inc · CUSIP 05464T104
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 29
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 5 listed it in both
- Shares listed
- 7,833,225
- combined, among listed positions
- Reported value
- $1.4bn
- combined, at the quarter end
Among the 92 comparable managers: 15 buyers (opened or added shares) and 12 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +1,256,338.
Managers listing AXSM in Q4 2025
29 of 29 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incexisting position · 1,509,870 shares now+472,422
- Invesco Ltdexisting position · 1,273,494 shares now+282,937
- Fidelity (FMR LLC)existing position · 1,181,622 shares now+253,739
- D. E. Shaw & Co.existing position · 549,113 shares now+252,826
- Two Sigma Advisers LPnew position · 188,500 shares now+188,500
Reductions
- Woodline Partners LPexisting position · 150,864 shares now-181,000
- Wellington Management Group LLPexisting position · 1,221,656 shares now-112,904
- Man Group PLCexisting position · 228,641 shares now-59,267
- Marshall Wace LLPexisting position · 320,568 shares now-57,456
- Neuberger Berman Group LLCexisting position · 69,483 shares now-21,695
New positions and exits
New (4)
Exited (1)
- Freestone Grove Partners LPwas $303k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2017 | 1 | $338k | n.a. | n.a. |
| Q3 2018 | 1 | $62k | n.a. | n.a. |
| Q1 2019 | 2 | $2.7m | n.a. | n.a. |
| Q2 2019 | 2 | $16m | n.a. | n.a. |
| Q3 2019 | 2 | $11m | n.a. | n.a. |
| Q4 2019 | 7 | $162m | n.a. | n.a. |
| Q1 2020 | 5 | $48m | n.a. | n.a. |
| Q2 2020 | 3 | $26m | n.a. | n.a. |
| Q3 2020 | 1 | $2.1m | n.a. | n.a. |
| Q1 2021 | 1 | $2.5m | n.a. | n.a. |
| Q3 2021 | 2 | $12m | n.a. | n.a. |
| Q1 2022 | 2 | $12m | n.a. | n.a. |
| Q2 2022 | 1 | $2.6m | n.a. | n.a. |
| Q3 2022 | 2 | $37m | n.a. | n.a. |
| Q4 2022 | 4 | $75m | n.a. | n.a. |
| Q1 2023 | 4 | $146m | n.a. | n.a. |
| Q2 2023 | 6 | $92m | n.a. | n.a. |
| Q3 2023 | 4 | $78m | n.a. | n.a. |
| Q4 2023 | 4 | $120m | 3 | 2 |
| Q1 2024 | 3 | $59m | 0 | 2 |
| Q2 2024 | 4 | $65m | 2 | 1 |
| Q3 2024 | 6 | $86m | 4 | 1 |
| Q4 2024 | 3 | $38m | 2 | 0 |
| Q1 2025 | 9 | $222m | 7 | 1 |
| Q2 2025 | 7 | $139m | 6 | 2 |
| Q3 2025 | 5 | $284m | 3 | 3 |
| Q4 2025 | 12 | $806m | 15 | 12 |
| Q1 2026 | 12 | $708m | 18 | 14 |
| Q2 2026 | 17 | $1.4bn | 24 | 11 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
AXSM and LLY →AXSM and JNJ →AXSM and VRTX →Choose a stock to compare with AXSM →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own AXSM, latest filings →Back to the 13F Explorer →